The United Kingdom (UK) has left the European Union (EU) and the transition period after Brexit comes to an end this year and from 1 January 2021 new regulations will apply. These changes will also affect the EU paediatric investigation plan (PIP) maintenance and procedures.
The UK competent authorities, the Medicines and Healthcare products Regulatory Agency (MHRA), recently published some preliminary guidance on the procedures and scenarios in the case of a no-deal Brexit with further guidance to follow. https://www.gov.uk/guidance/procedures-for-uk-pips-in-the-event-the-uk-leaves-the-eu-without-a-deal
Asphalion has already worked in more than 15 successful PIPs, so in case of any concerns related to paediatric development and PIPs, please contact us at info@asphalion.com.
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
A new technique allows the design of solid materia...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Han desarrollado un estudio para evaluar la correlación entre el teji...
Portal de biotecnología en España
¡Suscríbase a nuestro newsletter para estar al día con las últimas noticias y ofertas!
2013 © Biotech-Spain.com - Site Developments SL. Todos los derechos reservados. Terminos y Condiciones | Política de Privacidad
Articles
Directory